# Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/efficacy-and-safety-of-apremilast-an-oral-phosphodiesterase-4-inhibitor-in/

## Facts

| Field | Value |
| --- | --- |
| Author Names | C. Paul,Jennifer Clay Cather,Melinda Gooderham,Yves Poulin,Ulrich Mrowietz,C. Ferrandiz,J. Crowley,ChiaChi Hu,R.M. Stevens,Kara N. Shah,R. M. Day,Giampiero Girolomoni,A.B. Gottlieb |
| Citations | 480 |
| DOI | 10.1111/bjd.14164 |
| Fields | Biochemistry, Genetics and Molecular Biology,Immunology and Microbiology |
| Open Access | true |
| OA Status | hybrid |
| OA URL | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bjd.14164 |
| OpenAlex ID | https://openalex.org/W2131727392 |
| PMID | 26357944 |
| Type | article |
| Year | 2015 |

## Paper authors

- [Giampiero Girolomoni](https://scholariq.org/researchers/giampiero-girolomoni/)
- [Melinda Gooderham](https://scholariq.org/researchers/melinda-gooderham/)

## Paper journal

- [British Journal of Dermatology](https://scholariq.org/journals/british-journal-of-dermatology/)

## Paper primary topic

- [Phosphodiesterase function and regulation](https://scholariq.org/topics/phosphodiesterase-function-and-regulation/)

## Paper topics

- [Phosphodiesterase function and regulation](https://scholariq.org/topics/phosphodiesterase-function-and-regulation/)
- [Psoriasis: Treatment and Pathogenesis](https://scholariq.org/topics/psoriasis-treatment-and-pathogenesis/)
- [Adenosine and Purinergic Signaling](https://scholariq.org/topics/adenosine-and-purinergic-signaling/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.